Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.

Autor: Horwitz SM; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. horwitzs@mskcc.org.; New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA. horwitzs@mskcc.org., Nirmal AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rahman J; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Xu R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Drill E; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Galasso N; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ganesan N; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Davey T; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hancock H; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Perez L; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Maccaro C; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bahgat A; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Marzouk E; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cathcart E; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Moskowitz A; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Noy A; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kumar A; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Jacobsen E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Mehta-Shah N; Department of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA., Kim YH; Division of Oncology, Stanford University, Stanford, CA, USA.; Department of Dermatology, Stanford University, Stanford, CA, USA., Khodadoust M; Division of Oncology, Stanford University, Stanford, CA, USA.; Department of Dermatology, Stanford University, Stanford, CA, USA., Kotlov N; BostonGene Corporation, Boston, MA, USA., Nikitina A; BostonGene Corporation, Boston, MA, USA., Kudryashova O; BostonGene Corporation, Boston, MA, USA., Zubareva V; BostonGene Corporation, Boston, MA, USA., Zornikova K; BostonGene Corporation, Boston, MA, USA., Shin N; BostonGene Corporation, Boston, MA, USA., Sorokina M; BostonGene Corporation, Boston, MA, USA., Degryse S; BostonGene Corporation, Boston, MA, USA., Postovalova E; BostonGene Corporation, Boston, MA, USA., Bagaev A; BostonGene Corporation, Boston, MA, USA., Hosszu K; Department of Pediatrics and Immune Discovery & Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., McAvoy D; Department of Pediatrics and Immune Discovery & Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Boelens JJ; Department of Pediatrics and Immune Discovery & Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wu W; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Ciantra Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Appelt JW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Trevisani C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Amaka S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Merck and Co., Rahway, NJ, USA., Vardhana SA; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. vardhans@mskcc.org.; New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA. vardhans@mskcc.org.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. vardhans@mskcc.org.

Publikováno v: Nature medicine [Nat Med] 2024 Dec; Vol. 30 (12), pp. 3778.

Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.

Autor: Horwitz SM; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. horwitzs@mskcc.org.; New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA. horwitzs@mskcc.org., Nirmal AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rahman J; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Xu R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Drill E; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Galasso N; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ganesan N; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Davey T; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hancock H; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Perez L; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Maccaro C; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bahgat A; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Marzouk E; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cathcart E; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Moskowitz A; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Noy A; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kumar A; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Jacobsen E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Mehta-Shah N; Department of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA., Kim YH; Division of Oncology, Stanford University, Stanford, CA, USA.; Department of Dermatology, Stanford University, Stanford, CA, USA., Khodadoust M; Division of Oncology, Stanford University, Stanford, CA, USA.; Department of Dermatology, Stanford University, Stanford, CA, USA., Kotlov N; BostonGene Corporation, Boston, MA, USA., Nikitina A; BostonGene Corporation, Boston, MA, USA., Kudryashova O; BostonGene Corporation, Boston, MA, USA., Zubareva V; BostonGene Corporation, Boston, MA, USA., Zornikova K; BostonGene Corporation, Boston, MA, USA., Shin N; BostonGene Corporation, Boston, MA, USA., Sorokina M; BostonGene Corporation, Boston, MA, USA., Degryse S; BostonGene Corporation, Boston, MA, USA., Postovalova E; BostonGene Corporation, Boston, MA, USA., Bagaev A; BostonGene Corporation, Boston, MA, USA., Hosszu K; Department of Pediatrics and Immune Discovery & Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., McAvoy D; Department of Pediatrics and Immune Discovery & Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Boelens JJ; Department of Pediatrics and Immune Discovery & Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wu W; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Ciantra Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Appelt JW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Trevisani C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Amaka S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Merck and Co., Rahway, NJ, USA., Vardhana SA; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. vardhans@mskcc.org.; New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY, USA. vardhans@mskcc.org.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. vardhans@mskcc.org.

Publikováno v: Nature medicine [Nat Med] 2024 Sep; Vol. 30 (9), pp. 2517-2527. Date of Electronic Publication: 2024 Jun 17.

CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.

Autor: Park JH; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA. parkj6@mskcc.org.; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA. parkj6@mskcc.org.; Department of Medicine, Weill Cornell Medicine, New York City, NY, USA. parkj6@mskcc.org., Nath K; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Devlin SM; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Sauter CS; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Center for Cell Engineering, Sloan Kettering Institute, New York City, NY, USA.; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Palomba ML; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York City, NY, USA.; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Shah G; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York City, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Dahi P; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York City, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Lin RJ; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York City, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Scordo M; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York City, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Perales MA; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York City, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Shouval R; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York City, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Tomas AA; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Division of Hematology and Hemotherapy, Hospital General Universitario Gregorio Maranon, Madrid, Spain., Cathcart E; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Mead E; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Santomasso B; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Holodny A; Radiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Brentjens RJ; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Center for Cell Engineering, Sloan Kettering Institute, New York City, NY, USA.; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Riviere I; Center for Cell Engineering, Sloan Kettering Institute, New York City, NY, USA.; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Sadelain M; Center for Cell Engineering, Sloan Kettering Institute, New York City, NY, USA.

Publikováno v: Nature medicine [Nat Med] 2023 Jul; Vol. 29 (7), pp. 1710-1717. Date of Electronic Publication: 2023 Jul 03.

The Influence of Muscle Work on Metabolism in Varying Conditions of Diet

Autor: Cathcart, E. P., Burnett, W. A.

Publikováno v: Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character, 1926 May 01. 99(699), 405-426.

Externí odkaz: https://www.jstor.org/stable/81098

John James Rickard Macleod. 1876-1935

Autor: Cathcart, E. P.

Publikováno v: Obituary Notices of Fellows of the Royal Society, 1935 Dec 01. 1(4), 585-589.

Externí odkaz: https://www.jstor.org/stable/768990